Since 2018, there has been an increasing interest in the human diabetes medication group sodium-dependent glucose transporter 2 (SGLT2)-inhibitors (SGLT2i) as a potential treatment for EMS, as this class of drugs have been shown to reduce hyperinsulinemia and increase insulin sensitivity in horses [16–21]. This evidence concerns the gene INS and Hyperinsulinemia.